Aura Biosciences to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:

• SVB Securities Global Biopharma Conference on Thursday, February 16, 2023.
  Fireside Chat at 12:00 p.m. ET.
• 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023.
  Auditory & Ophthalmology Panel Discussion at 12:50 p.m. ET.

Live webcasts of the SVB fireside chat and Cowen panel discussion will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology indications. Aura’s lead VDC candidate, belzupacap sarotalocan (bel-sar; AU-011), consists of a virus-like particle conjugated with an anti-cancer agent. Bel-sar is designed to selectively target and destroy cancer cells and activate the immune system with the potential to create long-lasting anti-tumor immunity. Bel-sar is currently in development for ocular cancers, and Aura has initiated activities for the global Phase 3 trial evaluating first-line treatment of early-stage choroidal melanoma, a vision- and life-threatening form of eye cancer where standard of care with radiotherapy leaves patients with severe comorbidities, including major vision loss. Aura plans to pursue development of bel-sar across its ocular oncology franchise including for the treatment of patients with choroidal metastasis. In addition, leveraging Aura’s technology platform, Aura is developing bel-sar more broadly across multiple cancers, including in patients with non-muscle invasive bladder cancer (NMIBC). Aura is headquartered in Boston, MA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230209005136/en/

Investors and Media:

Alex Dasalla
Head of Investor Relations and Corporate Communications
[email protected]

Argot Partners
Matthew DeYoung
[email protected]

Source: Aura Biosciences Inc.

You May Also Be Interested In

• South African Food Science Leader Gunnar Sigge Begins Term as President of the Institute of Food Technologists
• Solana Price Prediction Targets $150 but Early Pepeto Wallets Could See 150x First
• TRON H1 2026 Strategy Report: Anchored by DeFi, Driven by AI to Lead Crypto's Next Cycle